Baird lowered the firm’s price target on Definitive Healthcare to $5 from $6 and keeps a Neutral rating on the shares. The firm said a combination of continued difficult macro environment and disruptions in the sales organization led to bookings performance below expectations.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DH:
- Definitive Healthcare price target lowered to $5 from $9 at Morgan Stanley
- Definitive Healthcare price target lowered to $6 from $8 at Canaccord
- Definitive Healthcare backs FY24 adjusted EPS view 32c-34c, consensus 34c
- Definitive Healthcare sees Q3 adjusted EPS 7c-8c, consensus 9c
- Definitive Healthcare reports Q2 adjusted EPS 9c, consensus 9c